Nausea Post ChemotherapyNCT07509905
TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
A study testing Transcutaneous electrical nerve stimulation and Antiemetic in people with Nausea Post Chemotherapy and Vomiting, run by Cairo University at 1 site in Egypt.
Trial summary
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting. Read more about this study
- Who is it for?
- Ages 40 to 60 years
- Conditions the study is for
- Nausea Post Chemotherapy, Vomiting, Transcutaneous Electrical Acupoint Stimulation
- What is being tested?
- Transcutaneous electrical nerve stimulation and Antiemetic
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Oct 2025to 18 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male and female patients who their ages between 40 and 60.
- All patients diagnosed with cancer and planned to receive TACE treatment with cisplatin (60 mg) as the main drug. The chemotherapy regimen will not include steroids.
- Karnofsky's score ≥60.
- All patients will receive the same antiemetic drug.
- None of them receiving other physical therapy modalities to treat nausea and vomiting.
- The skin of acupoint site receiving electrical acupoint stimulation must be intact and without visible evidence of injury
- All patient can tolerate mild discomfort following electrical stimulation.
- All patients enrolled in the study will have their informed consent.
Who cannot join
- Combined use of other venous chemotherapy within 5 days after Transarterial Chemoembolization
- Other confounding factors that may cause nausea and vomiting (such as intestinal obstruction, anorexia, and so on)
- Having vomited or used 5 HT3 receptor antagonists or other antiemetics within 24 hours before Transarterial Chemoembolization .
- Receiving concurrent radiotherapy
- Severe uncontrolled complications and unstable metastases
- Installing pacemaker, Pregnancy.
Show all 9Show fewer
- History of convulsions or seizure disorder.
- Cognitive dysfunction, unable to finish Scale
- Transcutaneous electrical acupoint stimulation treatment within the past year regardless of indication.
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.
Read the detailed description
Chemotherapy-induced nausea and vomiting significantly impacts the quality of life for 70%-80% of cancer patients receiving chemotherapy. The P6 acupressure point is traditionally used to relieve these symptoms and has shown benefits in pain relief and other conditions. If studies on Transcutaneous electrical acupoint stimulation yield positive results, it could be integrated as an effective method to manage chemotherapy-induced nausea and vomiting, enhancing patient comfort and treatment outcomes while potentially reducing the need for dosage adjustments. This study aims to address gaps in current treatments, improving management and quality of life for affected cancer patients.
- Conditions
- Nausea Post Chemotherapy, Vomiting, Transcutaneous Electrical Acupoint Stimulation, Acupuncture
- Being tested
- Transcutaneous electrical nerve stimulation, Antiemetic
- Medical subject headings
- Vomiting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcutaneous electrical nerve stimulationDevice
The acupoints were wiped with a moist cotton swab and then connected to the anode and cathode of the electrical stimulation generator through an electrode patch placed on the skin surface.
Continuous wave form mode was selected, and then the electric current produced continuous stimulation on the acupoints. Stimulation frequency was set at 4 Hz, and the default value was set as 10 mA, which was twice the sensory threshold (5 mA). The intensity was adjusted every 10 min to keep the patients comfortable, and its actual value ranged from 7 to 15 mA.
AntiemeticDrug
the drug is being taken once a day for 72 hours after introducing chemotherapy
| Study group | Role | What they receive |
|---|---|---|
| Transcutaneous electrical nerve stimulation group | Experimental | this group is going to take Transcutaneous electrical nerve stimulation at acupoint P6 and IL4 in additional to traditional anti-emetic drugs Receives: Device: Transcutaneous electrical nerve stimulation; Drug: Antiemetic |
| Traditional Group | Active comparator | this group is going to receive traditional anti-emetic drug Receives: Drug: Antiemetic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of nausea
The M. D. Anderson Symptom Inventory MD Anderson Symptom Inventory is a multi-symptom patient-reported outcome measure for clinical and research use. The MD Anderson Symptom Inventory 's thirteen core items include symptoms found to have the highest frequency and/or severity in patients with various cancers and treatment types. Each symptom is being scored between 0 and 10, were 0 means no effect and 10 means greatest severity.
Measured: At the day of chemotherapy administration and the following 5 days
Secondary outcomes (1)
Assessment of vomiting
Visual analog scale for anorexia is a widely used tool for assessing subjective symptoms, including anorexia. It consists of a horizontal or vertical line, typically 100 mm long, where patients mark their perceived intensity of a symptom-ranging from "no anorexia" to "worst possible anorexia"
Measured: At the day of chemotherapy administration and the following 5 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2026
- Study start15 Oct 2025
- Primary completion20 Jan 2026
- Study completion18 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nausea Post ChemotherapyStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nourhan Walid Shaban Ragab, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07509905
- Sponsor's protocol ID
- Nourhan-M.Sc
- Status last verified
- Mar 2026
- First submitted
- 28 Mar 2026
- Last updated
- 3 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
- ClinicalTrials.gov ID
- NCT07509905
- Acronym / sponsor ID
- Nourhan-M.Sc
- Conditions
- Nausea Post Chemotherapy, Vomiting, Transcutaneous Electrical Acupoint Stimulation, Acupuncture
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 15 Oct 2025 (actual)
- Primary completion
- 20 Jan 2026 (actual)
- Study completion
- 18 Feb 2026 (actual)
- First posted
- 3 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.
Detailed description
Chemotherapy-induced nausea and vomiting significantly impacts the quality of life for 70%-80% of cancer patients receiving chemotherapy. The P6 acupressure point is traditionally used to relieve these symptoms and has shown benefits in pain relief and other conditions. If studies on Transcutaneous electrical acupoint stimulation yield positive results, it could be integrated as an effective method to manage chemotherapy-induced nausea and vomiting, enhancing patient comfort and treatment outcomes while potentially reducing the need for dosage adjustments. This study aims to address gaps in current treatments, improving management and quality of life for affected cancer patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Transcutaneous electrical nerve stimulation group | Experimental | Device: Transcutaneous electrical nerve stimulation, Drug: Antiemeticthis group is going to take Transcutaneous electrical nerve stimulation at acupoint P6 and IL4 in additional to traditional anti-emetic drugs |
| Traditional Group | Active comparator | Drug: Antiemeticthis group is going to receive traditional anti-emetic drug |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Male and female patients who their ages between 40 and 60.
- All patients diagnosed with cancer and planned to receive TACE treatment with cisplatin (60 mg) as the main drug. The chemotherapy regimen will not include steroids.
- Karnofsky's score ≥60.
- All patients will receive the same antiemetic drug.
- None of them receiving other physical therapy modalities to treat nausea and vomiting.
Key exclusion criteria (9 listed)
- Combined use of other venous chemotherapy within 5 days after Transarterial Chemoembolization
- Other confounding factors that may cause nausea and vomiting (such as intestinal obstruction, anorexia, and so on)
- Having vomited or used 5 HT3 receptor antagonists or other antiemetics within 24 hours before Transarterial Chemoembolization .
- Receiving concurrent radiotherapy
- Severe uncontrolled complications and unstable metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcutaneous electrical nerve stimulationThe acupoints were wiped with a moist cotton swab and then connected to the anode and cathode of the electrical stimulation generator through an electrode patch placed on the skin surface. Continuous wave form mode was selected, and then the electric current produced continuous stimulation on the acupoints. Stimulation frequency was set at 4 Hz, and the default value was set as 10 mA, which was twice the sensory threshold (5 mA). The intensity was adjusted every 10 min to keep the patients comfortable, and its actual value ranged from 7 to 15 mA. | Device | Transcutaneous electrical nerve stimulation group |
| Antiemeticthe drug is being taken once a day for 72 hours after introducing chemotherapy | Drug | Traditional Group, Transcutaneous electrical nerve stimulation group |
Primary outcome
Assessment of nausea
Time frame: At the day of chemotherapy administration and the following 5 days
The M. D. Anderson Symptom Inventory MD Anderson Symptom Inventory is a multi-symptom patient-reported outcome measure for clinical and research use. The MD Anderson Symptom Inventory 's thirteen core items include symptoms found to have the highest frequency and/or severity in patients with various cancers and treatment types. Each symptom is being scored between 0 and 10, were 0 means no effect and 10 means greatest severity.
1 secondary outcome
Assessment of vomiting
Time frame: At the day of chemotherapy administration and the following 5 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2026.
Related trials for Nausea Post Chemotherapy
RecruitingPhase 2
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Enrolling by invitation
Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
RecruitingPhase 3
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Multiple Myeloma
Not yet recruiting
Chewing Gum Flavors to Reduce Postoperative Nausea and Vomiting After PIPAC
Postoperative Nausea and Vomiting (PONV), Peritoneal Metastases From Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcutaneous electrical nerve stimulation and Antiemetic in people with Nausea Post Chemotherapy and Vomiting, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of nausea (time frame: At the day of chemotherapy administration and the following 5 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.